psoriasis

Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Microbiome Report for Week Ending 12/1/18
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Bausch Health announces good Phase III results from psoriasis therapy
Bausch Health announces good Phase III results from psoriasis therapy
GoinPharma
Bausch Health
psoriasis
clinical trials
Bryhali
Flag link:
Bristol-Myers Squibb’s Psoriasis Drug Dazzles in Phase II Clinical Trial
Bristol-Myers Squibb’s Psoriasis Drug Dazzles in Phase II Clinical Trial
BioSpace
Bristol-Myers Squibb
BMS-986165
psoriasis
clinical trials
Flag link:
MC2 Therapeutics' psoriasis drug succeeds in Phase 3 trial
MC2 Therapeutics' psoriasis drug succeeds in Phase 3 trial
Biopharma Dive
MC2 Therapeutics
clinical trials
psoriasis
MC2-01
Taclonex
Flag link:
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Fierce Biotech
GSK
Dermavant
Roivant
CSO
tapinarof
psoriasis
atopic dermatitis
Flag link:
Skin treatment device-maker Clarify Medical raises $1m
Skin treatment device-maker Clarify Medical raises $1m
Mass Device
Clarify Medical
devices
psoriasis
Flag link:
Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Marketwatch
Valeant Pharmaceuticals
psoriasis
FDA
Duobrii
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
CP Wire
JNJ
NICE
Tremfya
psoriasis
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
JNJ
Tremfya
psoriasis
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
US approves UCB’s Cimzia for psoriasis
US approves UCB’s Cimzia for psoriasis
Pharma Times
FDA
UCB Pharma
Cimzia
psoriasis
Flag link:
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
CP Wire
AbbVie
EMA
Europe
risankizumab
psoriasis
Flag link:
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
AbbVie
psoriasis
risankizumab
Flag link:
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
CP Wire
UCB Pharma
CHMP
Cimzia
psoriasis
Flag link:
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
UCB Pharmaceuticals
Cimzia
psoriasis
Flag link:
Will Ilumya Kill Valeant's Psoriasis Dreams?
Will Ilumya Kill Valeant's Psoriasis Dreams?
Seeking Alpha
Sun Pharma
Ilumya
FDA
psoriasis
Siliq
Valeant Pharmaceuticals
Flag link:
Sun Pharma Receives Approval for New Plaque Psoriasis Drug
Sun Pharma Receives Approval for New Plaque Psoriasis Drug
CP Wire
Sun Pharma
psoriasis
Ilumya
FDA
Flag link:
An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D
An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D
Endpoints
immunotherapy
psoriasis
Escalier
R&D
Flag link:
Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Endpoints
Novartis
Cosentyx
psoriasis
Flag link:

Pages